Creative monetisation of de-prioritised IP is the next frontier for Big Pharma strategists
Despite their commitments to specialisation, large life sciences companies must not neglect the value of sidelined patents, know-how and other intangible assets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.